{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001050","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.791994+00:00","generated_at":"2026-05-16T10:53:26.191027+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries","bullets":["First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.","Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.","Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.","WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.","Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001050","json":"https://secwatch.observer/filing/0001437749-26-001050.json","markdown":"https://secwatch.observer/filing/0001437749-26-001050.md","text":"https://secwatch.observer/filing/0001437749-26-001050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/0001437749-26-001050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926001050/mbrx20260110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:53:26.191027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}